Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of “Moderate Buy” by Brokerages

Altimmune, Inc. (NASDAQ:ALT) has earned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $20.00.

ALT has been the subject of a number of analyst reports. UBS Group began coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, November 14th.

Institutional Investors Weigh In On Altimmune

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. B. Riley Wealth Advisors Inc. increased its position in shares of Altimmune by 12.9% in the 3rd quarter. B. Riley Wealth Advisors Inc. now owns 23,454 shares of the company’s stock valued at $144,000 after buying an additional 2,687 shares in the last quarter. Virtu Financial LLC bought a new stake in shares of Altimmune in the third quarter worth about $674,000. Barclays PLC raised its position in shares of Altimmune by 93.0% during the third quarter. Barclays PLC now owns 155,741 shares of the company’s stock worth $956,000 after purchasing an additional 75,064 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Altimmune by 4.7% during the 3rd quarter. Geode Capital Management LLC now owns 1,668,004 shares of the company’s stock valued at $10,244,000 after purchasing an additional 74,194 shares in the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Altimmune by 27.5% in the 3rd quarter. Wellington Management Group LLP now owns 197,232 shares of the company’s stock valued at $1,211,000 after purchasing an additional 42,553 shares during the period. Institutional investors own 78.05% of the company’s stock.

Altimmune Stock Performance

NASDAQ:ALT opened at $7.25 on Tuesday. The firm’s 50-day moving average is $8.07 and its 200-day moving average is $7.19. The company has a market cap of $515.66 million, a price-to-earnings ratio of -4.68 and a beta of 0.22. Altimmune has a 52-week low of $5.28 and a 52-week high of $14.84.

Altimmune (NASDAQ:ALT) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. The company had revenue of $0.01 million for the quarter. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. During the same period in the previous year, the business posted ($0.39) EPS. Equities analysts predict that Altimmune will post -1.36 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.